Evidence map›Paper›PMID 38836529›Full record

ArticleJournal of the National Cancer Institute. Monographs2024

Impact of a multicomponent navigation strategy on stigma among people living with HIV and Kaposi's sarcoma in Kenya: a qualitative analysis.

Sigrid M Collier, Aggrey Semeere, Linda Chemtai, Helen Byakwaga, Celestine Lagat, Miriam Laker-Oketta, Juliet Bramante, Ann Pacheco, Morvarid Zehtab, Alexis G Strahan and 9 more

Abstract read
In one paragraph

Article in Journal of the National Cancer Institute. Monographs, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Sigrid M CollierDepartment of Dermatology, University of Washington, Seattle, WA, USA.ORCID 0000-0002-4143-0408
Aggrey SemeereInfectious Disease Institute, Makerere University, Kampala, Uganda.ORCID 0000-0003-1826-2239
Linda ChemtaiAcademic Model Providing Access to Healthcare, Eldoret, Kenya.
Helen ByakwagaInfectious Disease Institute, Makerere University, Kampala, Uganda.ORCID 0000-0002-4799-1564
Celestine LagatAcademic Model Providing Access to Healthcare, Eldoret, Kenya.
Miriam Laker-OkettaInfectious Disease Institute, Makerere University, Kampala, Uganda.ORCID 0000-0002-6974-9437
Juliet BramanteSchool of Medicine, University of Washington, Seattle, WA, USA.
Ann PachecoDepartment of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-2002-4718
Morvarid ZehtabDepartment of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0009-0009-8129-3872
Alexis G StrahanDepartment of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-4763-0950
Merridy GrantWestern Australian Centre for Rural Health, University of Western, Australia.ORCID 0000-0002-7790-5102
Laura M BogartRAND Corporation, Santa Monica, CA, USA.ORCID 0000-0003-3182-5542
Ingrid V BassettDepartment of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-6920-6080
Naftali BusakhalaAcademic Model Providing Access to Healthcare, Eldoret, Kenya.ORCID 0000-0002-1229-3475
Jesse OpakasAcademic Model Providing Access to Healthcare, Eldoret, Kenya.ORCID 0000-0002-7073-4427
Toby MaurerDepartment of Dermatology, Indiana University, Indianapolis, IN, USA.ORCID 0000-0003-1968-3916
Jeffrey MartinDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-9773-3256
Samson KipronoAcademic Model Providing Access to Healthcare, Eldoret, Kenya.ORCID 0000-0001-5010-1369
Esther E FreemanDepartment of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-7751-9466

Funding

UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Sung-Jae Lee · 1997 to 2026
$53.5M
NPGH LEADERs YR12: OBSSR (Greenberg, Ngwafong Mukere) & NIBIB (Lee)D43TW009345 · FIC · UNIVERSITY OF WASHINGTON · PI Dibyadyuti Datta, Chandy C. John · 2017 to 2026
$15.2M
United States-East Africa HIV-Associated Malignancy Research Center (USEAHAMRC) for Career Development and the Prevention, Early Detection and Efficient Linkage to Care for Virus-related CancersU54CA254571 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARTIN, JEFFREY N · 2020 to 2025
$5.6M
Why do Patients Develop KSU54CA190153 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KAMBUGU, ANDREW DDUNGU, MARTIN, JEFFREY N · 2014 to 2019
$3.6M
Mentoring in patient-oriented research on HIV prevention in the US and South AfricaK24AI141036 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Ingrid Valerie Bassett · 2019 to 2026
$1.1M
Improving the Care Cascade for HIV-associated Kaposi's Sarcoma in sub-Saharan AfricaK23AI136579 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI FREEMAN, ESTHER E · 2018 to 2022
$1.1M
FIC NIH HHS D43 TW009345National Institute of Allergy and Infectious DiseasesNCI NIH HHS U54 CA190153NCI NIH HHS U54 CA254571NIAID NIH HHS K23 AI136579NIAID NIH HHS K24 AI141036NIH HHSNIH HHS U54 CA190153NIMH NIH HHS P30 MH058107Northern Pacific Global Health Fellows Program
6 · The paper itself

Abstract

Persons with HIV-associated Kaposi's sarcoma (KS) experience three co-existing stigmatizing health conditions: skin disease, HIV, and cancer, which contribute to a complex experience of stigmatization and to delays in diagnosis and treatment. Despite the importance of stigma among these patients, there are few proven stigma-reduction strategies for HIV-associated malignancies. Using qualitative methods, we explore how people with HIV-associated KS in western Kenya between August 2022 and 2023 describe changes in their stigma experience after participation in a multicomponent navigation strategy, which included 1) physical navigation and care coordination, 2) video-based education with motivational survivor stories, 3) travel stipend, 4) health insurance enrollment assistance, 5) health insurance stipend, and 6) peer mentorship. A purposive sample of persons at different stages of chemotherapy treatment were invited to participate. Participants described how a multicomponent navigation strategy contributed to increased knowledge and awareness, a sense of belonging, hope to survive, encouragement, and social support, which served as stigma mitigators, likely counteracting the major drivers of intersectional stigma in HIV-associated KS.

Indexed as

HIV InfectionsQualitative ResearchSarcoma, KaposiSocial StigmaAdultFemaleHumansKenyaMaleMiddle AgedPatient Navigation

Identifiers

PMID38836529
PMCPMC11151333

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.